Paul L. Berns - 20 Aug 2026 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Reporting relationship: Title: Executive Chair of the Board, Director
Issuer ticker: NMRA
Reported as of: 20 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Aug 2026, 19:10:04 UTC
Prior SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns

Key filing fact

Paul L. Berns filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 21 Aug 2026.

Key facts

This page summarizes Paul L. Berns's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Aug 2026, 19:10.

Change

Previous filing in this sequence was filed on 24 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001202769 Primary reporting owner

BERNS PAUL L

Relationship: Title: Executive Chair of the Board, Director
Address: C/O NEUMORA THERAPEUTICS, INC., 260 ARSENAL PLACE, SUITE 1, WATERTOWN
Signature: /s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns
Signature date: 21 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NMRA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +500,000
Change %
Price: $0.000000^*
Shares after: 500,000
Date: 20 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $1.52
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC remarks

Title: Executive Chair of the Board